Valuation: Ocugen, Inc.

Market Cap 460M 404M 373M 343M 648M 44.4B 658M 4.45B 1.75B 21.72B 1.73B 1.69B 74.8B P/E 2026 *
-5.89x
P/E 2027 * -5.5x
Enterprise Value 398M 349M 322M 296M 560M 38.37B 569M 3.85B 1.51B 18.77B 1.49B 1.46B 64.64B EV / Sales 2026 *
91.1x
EV / Sales 2027 * 41.8x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 week-7.48%
Current month-12.13%
1 month+12.29%
3 months-29.54%
6 months-18.80%
Current year-6.82%
1 week 1.15
Extreme 1.15
1.31
1 month 1.07
Extreme 1.072
1.47
3 years 0.33
Extreme 0.3264
2.35
5 years 0.33
Extreme 0.3264
15.88
Manager TitleAgeSince
Chief Executive Officer 62 27/09/2019
Director of Finance/CFO - 09/02/2026
Chief Operating Officer - 01/03/2026
Director TitleAgeSince
Chairman 62 27/09/2019
Director/Board Member 59 01/09/2013
Director/Board Member 59 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%-7.48%+31.07%+126.11% 460M
-0.49%-3.58%-0.84%+2.13% 49.18B
-3.10%-3.47%+370.99%+567.62% 39.58B
-0.46%+3.98%+5.44%+60.79% 34.69B
-1.14%-1.90%+26.94%-9.56% 34.42B
-1.82%-1.48%+0.52%+32.02% 27.11B
-3.54%-6.91% - - 16.21B
-1.82%-1.91%+69.28%+112.51% 15.36B
+1.17%+3.10%+15.87%+16.79% 14.05B
-2.25%-0.92%+15.77%-32.78% 13.02B
Average -1.49%-0.17%+59.45%+97.29% 27.07B
Weighted average by Cap. -1.43%-0.38%+75.82%+117.66%

Financials

2026 *2027 *
Net sales 4.37M 3.83M 3.53M 3.25M 6.15M 421M 6.24M 42.23M 16.56M 206M 16.4M 16.04M 709M 11.02M 9.66M 8.92M 8.21M 15.52M 1.06B 15.76M 107M 41.79M 520M 41.38M 40.47M 1.79B
Net income -76.84M -67.35M -62.18M -57.25M -108M -7.41B -110M -743M -291M -3.63B -289M -282M -12.48B -85.3M -74.76M -69.02M -63.55M -120M -8.23B -122M -825M -323M -4.02B -320M -313M -13.86B
Net Debt -62.5M -54.78M -50.57M -46.57M -88M -6.03B -89.39M -604M -237M -2.95B -235M -230M -10.15B -
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
-
Date Price Change
20/07/26 €1.172 -1.35%
17/07/26 €1.188 -0.50%
16/07/26 €1.194 -4.02%
15/07/26 €1.244 -1.11%
14/07/26 €1.258 +1.78%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.360USD
Average target price
11.43USD
Spread / Average Target
+740.34%

Quarterly revenue - Rate of surprise